Cargando…
Pharmacological characterization of a novel potent, selective, and orally active orexin 2 receptor antagonist, SDM‐878
AIMS: Recently, we identified a novel orexin 2 (OX(2)) receptor antagonist, SDM‐878 (2‐(3‐(2‐(1H‐pyrazol‐1‐yl)nicotinoyl)‐3,8‐diazabicyclo[3.2.1]octan‐8‐yl)‐3‐methoxyisonicotinonitrile). The purpose of the present study is to characterize the in vitro and in vivo pharmacological effects of SDM‐878....
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722660/ https://www.ncbi.nlm.nih.gov/pubmed/32337858 http://dx.doi.org/10.1002/npr2.12105 |